John M Zajecka
Overview
Explore the profile of John M Zajecka including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
551
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zajecka J, Stanford A, Memisoglu A, Martin W, Pathak S
Neuropsychiatr Dis Treat
. 2019 May;
15:795-808.
PMID: 31040679
Background: The endogenous opioid system is a fundamental regulator of mood in humans. Previously reported clinical trials have demonstrated the efficacy of the investigational agent buprenorphine/samidorphan (BUP/SAM) combination, an opioid-system...
2.
Aaronson S, Sears P, Ruvuna F, Bunker M, Conway C, Dougherty D, et al.
Am J Psychiatry
. 2017 Apr;
174(7):640-648.
PMID: 28359201
Objective: The Treatment-Resistant Depression Registry investigated whether adjunctive vagus nerve stimulation (VNS) with treatment as usual in depression has superior long-term outcomes compared with treatment as usual only. Method: This...
3.
Sanacora G, Johnson M, Khan A, Atkinson S, Riesenberg R, Schronen J, et al.
Neuropsychopharmacology
. 2016 Sep;
42(4):844-853.
PMID: 27681442
The objective of this study was to investigate the efficacy and safety of adjunctive lanicemine (NMDA channel blocker) in the treatment of major depressive disorder (MDD) over 12 weeks. This...
4.
Zajecka J, Fava M, Shelton R, Barrentine L, Young P, Papakostas G
J Clin Psychiatry
. 2016 Apr;
77(5):654-60.
PMID: 27035404
Objective: To evaluate remission and recovery, safety, and tolerability for up to 12 months of open-label adjunctive L-methylfolate calcium 15 mg. Method: Subjects in this analysis were adult outpatients (18-65...
5.
Shelton R, Pencina M, Barrentine L, Ruiz J, Fava M, Zajecka J, et al.
J Clin Psychiatry
. 2015 Nov;
76(12):1635-41.
PMID: 26613389
Objective: Adjunctive treatment with L-methylfolate calcium significantly improved treatment outcomes in patients with major depressive disorder (MDD) and an inadequate response to antidepressants. This post hoc exploratory analysis evaluated baseline...
6.
Papakostas G, Shelton R, Zajecka J, Bottiglieri T, Roffman J, Cassiello C, et al.
J Clin Psychiatry
. 2014 May;
75(8):855-63.
PMID: 24813065
Objective: Specific genetic or biological markers may predict inadequate response to therapy for major depressive disorder (MDD). The objective of the current post hoc analysis was to evaluate the effect...
7.
Zajecka J
J Clin Psychiatry
. 2013 Nov;
74 Suppl 2:9-13.
PMID: 24191972
Remission is the standard of care in major depressive disorder (MDD). However, even in patients who respond to treatment and achieve remission, residual symptoms significantly inhibit functionality and increase the...
8.
Papakostas G, Vitolo O, Ishak W, Rapaport M, Zajecka J, Kinrys G, et al.
J Clin Psychiatry
. 2013 Jan;
73(12):1541-7.
PMID: 23290327
Objective: To study ziprasidone monotherapy for major depressive disorder, defined according to the DSM-IV. Method: One hundred twenty outpatients were enrolled between June 2008 and September 2010 in a 12-week...
9.
Papakostas G, Shelton R, Zajecka J, Etemad B, Rickels K, Clain A, et al.
Am J Psychiatry
. 2012 Dec;
169(12):1267-74.
PMID: 23212058
Objective: The authors conducted two multicenter sequential parallel comparison design trials to investigate the effect of L-methylfolate augmentation in the treatment of major depressive disorder in patients who had a...
10.
Fava M, Shelton R, Zajecka J
J Clin Psychiatry
. 2011 Sep;
72(8):e25.
PMID: 21899813
Helping patients with major depressive disorder achieve symptom-free remission with antidepressant therapy remains challenging. In this activity, 3 investigators discuss the results of a 2-trial, multicenter, randomized, double-blind, placebo-controlled study...